European Neuropsychopharmacology
Volume 20, Issue 8 , Pages 535-544 , August 2010

Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder

Received 11 September 2009 ,Revised 13 December 2009 ,Accepted 20 December 2009.

References 

  1. Avissar S, Schreiber G. Toward molecular diagnostics of mood disorders in psychiatry. Trends. Mol. Med. 2002;8:294–300
  2. Baron M. Manic-depression genes and the new millennium: poised for discovery. Mol. Psychiatry. 2002;7:342–358
  3. Bocchio-Chiavetto L, Miniussi C, Zanardini R, Gazzoli A, Bignotti S, Specchia C, et al. 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neurosci. Lett. 2008;437:130–134
  4. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry. 2001;50:260–265
  5. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res. 2006;1118:176–182
  6. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–129
  7. Comings DE, MacMurray JP. Molecular heterosis: a review. Mol. Genet. Metab. 2000;71:19–31
  8. Dagher A, Owen AM, Boecker H, Brooks DJ. Mapping the network for planning: a correlational PET activation study with the Tower of London task. Brain. 1999;122:1973–1987
  9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials. 1986;7:177–188
  10. Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, Szczepankiewicz A, et al. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics. 2008;9:1595–1603
  11. Domschke K, Lawford B, Laje G, Berger K, Young R, Morris P, et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int. J. Neuropsychopharmacol. 2009;23:1–9
  12. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch. Gen. Psychiatry. 1997;54:597–606
  13. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257–269
  14. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 1997;315:629–634
  15. Fava M. Management of nonresponse and intolerance: switching strategies. J. Clin. Psychiatry. 2000;61:10–12
  16. Fava M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry. 2003;53:649–659
  17. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr. Clin. North Am. 1996;19:179–200
  18. Foltynie T, Lewis SG, Goldberg TE, Blackwell AD, Kolachana BS, Weinberger DR, et al. The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J. Neurol. 2005;252:833–838
  19. Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J. Psychiatr. Res. 1998;32:255–259
  20. Gartner A, Staiger V. Neurotrophin secretion from hippocampal neurons evoked by long-term-potentiation-inducing electrical stimulation patterns. Proc. Natl. Acad. Sci. U. S. A. 2002;99:6386–6391
  21. Gratacòs M, Soria V, Urretavizcaya M, González JR, Crespo JM, Bayés M, et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J. 2008;8:101–112
  22. Green E, Craddock N. Brain-derived neurotrophic factor as a potential risk locus for bipolar disorder: evidence, limitations, and implications. Curr. Psychiatry Rep. 2003;5:469–476
  23. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J. Clin. Psychiatry. 1993;54:405–418
  24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002;21:1539–1558
  25. Huuhka K, Anttila S, Huuhka M, Leinonen E, Rontu R, Mattila K, et al. Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T are not associated with response to electroconvulsive therapy in major depressive disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2007;257:31–35
  26. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, et al. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom. Med. 2005;67:703–706
  27. Jeste DV, Harris MJ, Krull A, Kuck J, McAdams LA, Heaton R. Clinical and neuropsychological characteristics of patients with late-onset schizophrenia. Am. J. Psychiatry. 1995;152:722–730
  28. Kang R, Chang H, Wong M, Choi M, Park J, Lee H, et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J. Psychopharmacol. 2009;1–9
  29. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol. Psychiatry. 2008;1–28
  30. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J. Clin. Psychopharmacol. 2006;26:128–134
  31. Lee BH, Kim H, Park SH, Kim YK. Decreased plasma BDNF level in depressive patients. J. Affect. Disord. 2007;101:239–244
  32. Licinio J, Dong C, Wong ML. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch. Gen. Psychiatry. 2009;66:488–497
  33. Linnarsson S, Bjorklund A, Ernfors P. Learning deficit in BDNF mutant mice. Eur. J. Neurosci. 1997;9:2581–2587
  34. Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, et al. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science. 1990;247:1446–1451
  35. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959;22:719–748
  36. Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S, et al. Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatr. Genet. 2006;16:49–50
  37. Michelon L, Meira-Lima I, Cordeiro Q, Miguita K, Breen G, Collier D, et al. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci. Lett. 2006;403:288–293
  38. Monteggia LM, Luikart B, Barrot M, Theobold D, Malkovska I, Nef S, et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol. Psychiatry. 2007;61:187–197
  39. Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004;20:439–444
  40. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002;34:13–25
  41. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 1995;15:7539–7547
  42. Nierenberg AA. Predictors of response to antidepressants general principles and clinical implications. Psychiatr. Clin. North Am. 2003;26:345–352
  43. Nitta A, Ohmiya M, Sometani A, Itoh M, Nomoto H, Furukawa Y, et al. Brain-derived neurotrophic factor prevents neuronal cell death induced by corticosterone. J. Neurosci. Res. 1999;57:227–235
  44. Pare CM, Rees L, Sainsbury MJ. Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet. 1962;2:1340–1343
  45. Rajewska-Rager A, Skibińska M, Szczepankiewicz A, Kapelski P, Dmitrzak-Weglarz M, Leszczyńska-Rodziewicz A, et al. Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression. Psychiatr. Pol. 2008;42:915–923
  46. Real E, Gratacòs M, Soria V, Escaramís G, Alonso P, Segalàs C, et al. A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive–compulsive disorder. Biol. Psychiatry. 2009;66:674–680
  47. Rogoz Z, Legutko B. Combined treatment with imipramine and metyrapone induces hippocampal and cortical brain-derived neurotrophic factor gene expression in rats. Pharmacol. Rep. 2005;57:840–844
  48. Russo-Neustadt AA, Beard RC, Huang YM, Cotman CW. Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neuroscience. 2000;101:305–312
  49. Russo-Neustadt AA, Ha T, Ramirez R, Kesslak JP. Physical activity-antidepressant treatment combination: impact on brain-derived neurotrophic factor and behavior in an animal model. Behav. Brain Res. 2001;120:87–95
  50. Russo-Neustadt AA, Alejandre H, Garcia C, Ivy AS, Chen MJ. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuro-psychopharmacology. 2004;29:2189–2199
  51. Rybakowski JK, Suwalska A, Skibinska M, Szczepankiewicz A, Leszczynska-Rodziewicz A, Permoda A, et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry. 2005;38:166–170
  52. Rybakowski JK, Suwalska A, Skibinska M, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J. Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007;144B:820–823
  53. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 2003;23:349–357
  54. Sartorius N. The economic and social burden of depression. J. Clin. Psychiatry. 2001;62:8–11
  55. Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, et al. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol. Psychiatry. 2005;58:307–314
  56. Sederer LI, Thorbeck J. First do no harm: short-term inpatient psychotherapy of the borderline patient. Hosp. Community Psychiatry. 1986;37:692–69759
  57. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 2002;22:3251–3261
  58. Simpson S, Baldwin RC, Jackson A, Burns AS. Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol. Med. 1998;28:1015–1026
  59. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 1997;56:131–137
  60. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al. Treatment resistant depression: methodological overview and operational criteria. Eur. Neuropsychopharmacol. 1999;9:83–91
  61. Szczepankiewicz A, Rajewska-Rager A, Dmitrzak-Weglarz M, Gattner K, Kapelski P, Kaczmarkiewicz-Fass M, et al. Lack of association of 1287A/G NET and Val66Met BDNF polymorphisms with response to antidepressants. Eur. Neuropsychopharmacol. 2007;17:375–376
  62. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J. Clin. Psychiatry. 1997;58:23–29
  63. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003;123B:19–22
  64. Ventimiglia R, Mather PE, Jones BE, Lindsay RM. The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur. J. Neurosci. 1995;7:213–222
  65. Ventriglia M, Bocchio Chiavetto L, Benussi L, Binetti G, Zanetti O, Riva MA, et al. Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Mol. Psychiatry. 2002;7:136–137
  66. Wilkie MJ, Smith D, Reid IC, Day RK, Matthews K, Wolf CR, et al. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet. Genomics. 2007;17:207–215
  67. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe — a critical review and appraisal of 27 studies. Eur. Neuropsychopharmacol. 2005;15:357–376
  68. Wu TW, Yang B, Cai SR, Cui CS. Brain-derived neurotrophic factor gene polymorphism (G196A) and paroxetine response in female depressive disorder. Prog. Obstet. Gynecol. 2008;17:585–588
  69. Xu H, Qing H, Lu W, Keegan D, Richardson JS, Chlan-Fourney J. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci. Lett. 2002;321:65–68
  70. Yoshida K, Higuchi H, Kamata M, Takahashi H, Inoue K, Suzuki T, et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J. Psychopharmacol. 2007;21:650–656

PII: S0924-977X(09)00282-X

doi: 10.1016/j.euroneuro.2009.12.005

European Neuropsychopharmacology
Volume 20, Issue 8 , Pages 535-544 , August 2010

Article Tools

* Image Usage & Resolution